BRAF and melanoma: Potential BRAF inter-tumor heterogeneity is clinically important because of the risk of treating patients with unnecessary targeted therapies (loss of mutation in metastasis) or disturbing beneficial targeted therapies from patients (mutations in metastasis but not in primary melanoma).